Results 21 to 30 of about 2,519 (184)
Frontiers in Medicine, 2020 Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron +39 more
doaj +2 more sources
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran [PDF]
Drug Design, Development and Therapy, 2016 Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous ...
Sié P
doaj +1 more source
Idarucizumab Reversal in Subdural Hemorrhage: A Single-Center Experience [PDF]
LifePrompt reversal of anticoagulation in the elderly population with subdural hematoma (SDH) is critical to reduce morbidity and facilitate timely surgical intervention. In patients receiving dabigatran, idarucizumab provides rapid anticoagulation reversal.
Anita Mrvar Brečko +5 more
doaj +2 more sources
Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke [PDF]
Frontiers in Neurology, 2019 We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery following the antagonization of dabigatran with idarucizumab.
Maren Hieber, Juergen Bardutzky
doaj +2 more sources
Intravenous thrombolysis for acute cerebral embolism during atrial fibrillation ablation: a case report and systematic review with meta-analysis [PDF]
Frontiers in Cardiovascular MedicineIntroductionPeriprocedural stroke represents a clinically important complication of atrial fibrillation ablation, and effective anticoagulation remains essential for risk reduction.
Bin Cai +5 more
doaj +2 more sources
Future Science OA, 2021 Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.
Eran Kalmanovich +12 more
doaj +2 more sources
PLoS ONE, 2019 BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke +7 more
doaj +2 more sources
Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
Case Reports in Neurology, 2016 We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day.
Waldemar Kafke +2 more
doaj +2 more sources
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
Therapeutics and Clinical Risk Management, 2018 Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
doaj +1 more source
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +6 more sources